Corporate Profile

We are an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, we seek to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. Our OMNI Surgical System is a safe, minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the leading cause of irreversible blindness. Our TearCare System is commercially available today as a wearable, office-based thermal eyelid technology that enables the controlled application of localized heat to the eyelids. TearCare is in development for the treatment of the signs and symptoms of evaporative dry eye, the primary form of dry eye disease which is the number one reason for a patient visit to an eyecare provider.

Stock Infomation

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

14 Jul '21
MENLO PARK, Calif. , July 14, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. , a growth-stage medical device company focused on the development and commercialization of proprietary devises that target the underlying causes of the world’s most prevalent eye diseases, today announced the pricing of

Recent Events

More events are coming soon.

Featured Reports

More information is coming soon.